# Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)

> **NCT04953312** · NA · WITHDRAWN · sponsor: **Assistance Publique - Hôpitaux de Paris**

## Conditions studied

- Severe/Moderate Coronavirus
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndromes
- Old Age

## Interventions

- **BIOLOGICAL:** Blood samples

## Key facts

- **NCT ID:** NCT04953312
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-01
- **Primary completion:** 2023-12
- **Final completion:** 2024-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Abandonment of the study project
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04953312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04953312, "Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT04953312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*